Authors: Valerie Rodrigue, Nicole E. Basta, Katie Gravagna

Year: 2024

DOI: 10.1111/tmi.13979

Summary#

This paper reviews clinical trials for vaccine and monoclonal antibody candidates designed to prevent Nipah and Hendra diseases in humans.

Key Findings#

• Three vaccine candidates (Hendra Virus Soluble Glycoprotein Vaccine [HeV-sG-V], PHV02, and mRNA-1215) and one mAb (m102.4) have registered human clinical trials.
• All trials are phase 1, dose-ranging trials taking place in the United States of America or Australia and enrolling healthy adults.

Methodology#

• Study Type: Scoping Review
• Geographic Focus: [‘United States of America’, ‘Australia’]
• Time Period: Up to June 2023

Topics#

Epidemiology, Clinical, Virology

Relevance#

The paper provides an overview of the clinical trials for vaccine and monoclonal antibody candidates that could potentially prevent Nipah and Hendra diseases, contributing to the ongoing research and development efforts.

Source#

[Download PDF](/pdfs/public-health-policy/Tropical Med Int Health - 2024 - Rodrigue - Current progress towards prevention of Nipah and Hendra disease in humans A.pdf)